Kelly A. Kramer
At a glance: Kelly A. Kramer is Director at Gilead Sciences (GILD). Their latest SEC Form 4, filed Nov 16, 2026, reported a sale of $282K. On file: 0 purchase lines ($0) and 6 sale lines ($2.5M).
Disclosed holdings: about $224K of GILD stock: 1,339 shares reported on their latest Form 4 (filed Nov 16, 2026), valued at the Nov 19, 2026 close of $167.13. This counts only GILD shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.
Director at Gilead Sciences, Inc. (GILD)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
Kelly A. Kramer's InsiderPrint
6 trades from SEC Form 4 filings, 2025 to 2026, drawn as one fingerprint.
Reading this print: Almost only sells, trading about 6 times a year, typically $357K a trade; most sales are on a pre-planned 10b5-1 schedule; trades in the same month most years.
- Bump outward: a purchase (0)
- Dent inward: a sale (6)
- One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.
Insiders with a similar print
- Larry KrausSvp, Cio · OLLI · 100% match
- Richard SteinmeierCEO · LPLA · 100% match
- Lee HeesonEvp, Head Of Incyte Intl · INCY · 100% match
- Paul Jonathan BrodyCFO · IBKR · 100% match
- John A. RoushDirector · AEIS · 100% match
Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Nov 16SEC | GILDGilead Sciences, Inc. | Sell Plan | 1,67610,039 held (−14%) | $168.23 | $282K | -0.6% |
| Nov 16SEC | GILDGilead Sciences, Inc. | Sell Plan | 3,8006,239 held (−38%) | $169.44 | $644K | -1.4% |
| Nov 16SEC | GILDGilead Sciences, Inc. | Sell Plan | 4,7001,539 held (−75%) | $170.49 | $801K | -2.0% |
| Nov 16SEC | GILDGilead Sciences, Inc. | Sell Plan | 2001,339 held (−13%) | $171.44 | $34K | -2.5% |
| Dec 1SEC | GILDGilead Sciences, Inc. | Sell Plan | 2,8061,339 held (−68%) | $127.11 | $357K | +31.5% |
| Dec 1SEC | GILDGilead Sciences, Inc. | Sell Plan | 2,8051,339 held (−68%) | $127.10 | $357K | +31.5% |
- Sell
Director Kelly A. Kramer sold $282K of GILD at $168.23 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Kelly A. Kramer sold $644K of GILD at $169.44 — cuts the stake by 38%; pre-scheduled 10b5-1 plan sale.
- Sell
Director Kelly A. Kramer sold $801K of GILD at $170.49 — cuts the stake by 75%; pre-scheduled 10b5-1 plan sale.
- Sell
Director Kelly A. Kramer sold $34K of GILD at $171.44 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Kelly A. Kramer sold $357K of GILD at $127.11 — cuts the stake by 68%; pre-scheduled 10b5-1 plan sale.
- Sell
Director Kelly A. Kramer sold $357K of GILD at $127.10 — cuts the stake by 68%; pre-scheduled 10b5-1 plan sale.
Follow Kelly A. Kramer
Get one email when Kelly A. Kramer files a new purchase or sale. Free.
At most one email a day about Kelly A. Kramer, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.